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Objective: Osteoarthritis (OA) is a non-rheumatologic joint disease characterized by progressive
degeneration of the cartilage extra-cellular matrix (ECM), enhanced subchondral bone remodeling,
activation of synovial macrophages and osteophyte growth. Inhibition of calcineurin (Cn) activity
through tacrolimus (FK506) in in vitro monolayer chondrocytes exerts positive effects on ECM marker
expression. This study therefore investigated the effects of FK506 on anabolic and catabolic markers of
osteoarthritic chondrocytes in 2D and 3D in vitro cultures, and its therapeutic effects in an in vivo rat
model of OA.
Methods: Effects of high and low doses of FK506 on anabolic (QPCR/histochemistry) and catabolic (QPCR)
markers were evaluated in vitro on isolated (2D) and ECM-embedded chondrocytes (explants, 3D pel-
lets). Severe cartilage damage was induced unilaterally in rat knees using papain injections in combi-
nation with a moderate running protocol. Twenty rats were treated with FK506 orally and compared to
twenty untreated controls. Subchondral cortical and trabecular bone changes (longitudinal microCT) and
macrophage activation (SPECT/CT) were measured. Articular cartilage was analyzed ex vivo using
contrast enhanced microCT and histology.
Results: FK506 treatment of osteoarthritic chondrocytes in vitro induced anabolic (mainly collagens) and
reduced catabolic ECM marker expression. In line with this, FK506 treatment clearly protected ECM
integrity in vivo by markedly decreasing subchondral sclerosis, less development of subchondral pores,
depletion of synovial macrophage activation and lower osteophyte growth.
Conclusion: FK506 protected cartilage matrix integrity in vitro and in vivo. Additionally, FK506 treatment
in vivo reduced OA-like responses in different articular joint tissues and thereby makes Cn an interesting
target for therapeutic intervention of OA.
 2014 Osteoarthritis Research Society International. Published by Elsevier Ltd. All rights reserved.Introduction
FK506 (Tacrolimus, Prograf) is an immunosuppressive drug
discovered by Kino et al. in the 1980s1. Since then, it has been used: M. Siebelt, Department of
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lt).
ternational. Published by Elsevier Lclinically for an increasing number of immunological disorders.
FK506 exerts its therapeutic effects by suppression of T-cell activa-
tion, without markedly affecting bone marrow cell differentiation
and proliferation2. Through binding to FK506-binding proteins
(FKBPs), FK506 inhibits the activity of ubiquitously expressed cal-
cium/calmodulin dependent calcineurin (Cn). As a consequence, the
Cn mediated dephosphorylation of transcription factors of the nu-
clear factorof activatedT-cells (NFATs) family (NFAT1-4) is inhibited.
Besides their role in T-cell activation, Cn and NFATs are now also
known to play a role in physiological processes in many other celltd. All rights reserved.
M. Siebelt et al. / Osteoarthritis and Cartilage 22 (2014) 591e600592and tissue types and pathological conditions like cancer, degener-
ative brain diseases and cardiac hypertrophy3. FK506 has proven to
be useful in reducing inﬂammation and alleviating symptoms in
patients with inﬂammatory (rheumatoid) arthritis4,5. Interestingly,
the Cn/NFAT signaling cascade is also reported to play a role in bone
remodeling6 and chondrogenesis7. FK506 has been shown to
induce chondrogenic differentiation of murine chondroprogenitor
cells8. This suggests that patients with non-inﬂammatory joint
diseases, like osteoarthritis (OA), also might beneﬁt from a treat-
ment with Cn inhibitors.
OA is a complex progressive disease and a disturbed balance
between anabolic and catabolic activity of chondrocytes is an early
pathophysiological event leading to matrix degradation. Progres-
sion of OA ﬁnally results in severe deterioration of articular cartilage
and involves pathological changes throughout the joint, like
extensive subchondral bone remodeling9 and activation of synovial
macrophages10. We reported earlier that FK506 treatment of
monolayer cultured osteoarthritic cells enhanced expression of
anabolic markers like collagen type II (COL2), but suppressed rele-
vant catabolic, hypertrophy and mineralization markers11,12.
Another Cn inhibitor, cyclosporine A (CsA) showed similar effects on
anabolic and catabolic activity of OA chondrocytes and reduced
cartilage damage in a collagenase induced OA mouse model13.
However, this study only measured macroscopical and microscop-
ical cartilage damage ex vivo and did not investigate possible effects
of Cn inhibitiononother tissues of the joint, like bone and synovium.
Recently, we established a novel rat OA model using a combi-
nation of papain injections with a running protocol to induce severe
knee joint articular cartilage degradation together with prominent
involvement of subchondral bone and synovial macrophages14. The
current study aimed to elucidate the effects of systemic FK506
treatment in this OA animal model. We ﬁrst characterized whether
both low and high concentrations of FK506 modulate anabolic
markers in OA chondrocytes in monolayer cultures. Since chon-
drocytes reside in an extra-cellular matrix (ECM) in vivo, we addi-
tionally investigated whether low dose FK506 treatment remains
beneﬁcial for ECM-embedded chondrocytes in ex vivo explants and
pellet cultures. Finally, we tested modulating effects of FK506 in an
animal model for severe cartilage degradation and analyzed artic-
ular cartilage (ex vivo mCT and histology), subchondral bone (in vivo
mCT) and synovial macrophages activation (in vivo SPECT/CT) 6 and
12 weeks after induction of cartilage damage.
Methods
FK506 effects on osteoarthritic chondrocytes in vitro
Human articular cartilage was explanted from macroscopically
normal areas of femoral condyles and tibial plateaus of patients
(N ¼ 9, between 55 and 82 years old) undergoing total knee
replacement surgery for OA (MEC2004-322). Isolation of primary
osteoarthritic human articular chondrocytes from cartilage tissue
under standard conditions (cytokine-free Dulbecco’s modiﬁed Ea-
gle’s medium (DMEM) with 4.5 g/L glucose, 10% fetal calf serum
(FCS), 50 mg/mL gentamycin and 1.5 mg/mL fungizone; all Invi-
trogen, Paisley, Scotland, UK, adjusted to 380 mOsm by adding
sterile sodium chloride) and monolayer experiments were per-
formed as described earlier11. In short, passage 1 cells were seeded
in 2D monolayer, stimulated with 0, 62 or 620 nM FK506 after
24 h and harvested for RNA analysis (quantitative RT-PCR) 6 days
later. Experiments were performed at least in technical duplicates
from four OA donors. In addition to 2D cultures, passage 2 cells
from four OA donors were cultured as 3D pellets (2  105 cells/
pellet) for 21 days inmedium (380mOsm)with or without addition
of 62 nM FK50611.To investigate the effects of FK506 on OA chondrocytes
embedded in their ECM, 6 mm diameter full-thickness explants
from femoral condyles and tibial plateaus of ﬁve OA donors were
cultured as described before11 and cultured in medium
(380 mOsm) with or without 62 nM FK506 for 7 days.
RNA and protein analysis by RT-QPCR and histology
RNA from monolayer and explant cultures was extracted, puri-
ﬁed and quantiﬁed, and cDNA was synthesized and quantiﬁed by
RT-QPCR reactions as described earlier12,15. RNA abundance was
normalized to an index of the three most stable reference genes
(GAPDH, HPRT1, 18sRNA or UBC) replicate values were averaged per
condition per patient and gene expression was calculated as fold
change of control condition (0 nM FK506)11. Primer sequences for
COL2, ACAN, MMP1, MMP13, MMP13, ADAMTS4 and ADAMTS5 were
adopted from Uitterlinden et al.15, for COL1 from Das et al.16, and for
VCAN/CSPG2 fromMartin et al.17. To quantify expression of COL9 and
COL11, the following primers were tested for similar ampliﬁcation
efﬁciency and speciﬁcity16, and were used as respectively 20 ml
TaqMan and SYBR Green I reactions: HsCOL9A1_F GCAGCT
CATGGCAAGTTTCTCT, COL9A1_R GCTTTGCTGTGCTGGGAAAA and
COL9A1_FAM TGAAGTTCAAATGGAACAGAAACTTGAGGATTATCTG;
HsCOL11a1_Fw AGGAGAGTTGAGAATTGGGAATC, COL11A1_Rv TGG
TGATCAGAATCAGAAGTTCG.
The expression data are presented as 2DDCt values based on
publication by Livak & Schmittgen18. The cDNA abundances of each
gene of interest were normalized to an index of three stable
expressed reference genes to generate a normalized, so-called
2DCt, value. Replicate values were averaged per condition, per
patient, and ﬁnally expressed as fold change difference relative to
the control condition (i.e., without FK506 treatment) and repre-
senting a 2DDCt value. The Col2/Col1 ratio, like the VCAN/CSPG2
ratio, relates the expression levels of both genes to one another.
Relative higher Col2 expression, as compared to Col1, is indicative
of a relatively better preserved chondrocyte-speciﬁc gene expres-
sion. This also holds for VCAN/CSPG2 ratios, and was used earlier as
a measure of de-differentiation of chondrocytes19,20.
(Immuno)histochemical staining for COL2 and GAG on 3D pellet
cultures was performed as described before21. Staining intensities
of pellets were quantiﬁed using ImageJ 1.42 software (http://rsb.
info.nih.gov/ij/download.html).
FK506 therapeutic effects in a rat model for severe OA
Forty 16-week-old male Wistar rats (Charles River Netherlands
BV, Maastricht, the Netherlands) were housed in the animal facility
of the Erasmus Medical Centre, with a 12-h lightedark regimen, at
21C during the experimental period, and received standard food
pellets and water ad libitum. OA-like articular destruction was
induced in all animals, which were then divided over two groups:
20 rats served as untreated controls and 20 rats were treated during
the experiment with FK506. FK506 treated animals received FK506
suspension (1 mg/kg)22 through oral probing, 5 days aweek, not on
weekends.
Severe cartilage damage was induced using intra-articular
papain injections in the left knee joints combined with exposure
to a moderate exercise protocol as described before14. In short, all
animals received three intra-articular injection that consisted of
15 ml 4% (w/v) papain solution (type IV, double crystallized,
15 units/mg, SigmaeAldrich, St. Louis, MO, USA) with 15 ml 0.03 M
L-cystein (SigmaeAldrich)23. Their contralateral knee joint served
as an internal healthy control. All rats were forced to run on a
motorized rodent treadmill (LE-8700; Panlab Harvard Apparatus,
Barcelona, Spain) for 6 weeks covering a total distance of 15 km14.
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baseline, 6 weeks and 12 weeks with mCT to measure subchondral
bone changes24. At 6 and 12 weeks, 10 rats in both groups were
selected for a full analysis sequence. This sequence consisted of
SPECT/CT to quantify in vivo macrophage activation25, and ex vivo
Equilibrium Partioning of an Ionic Contrast agent using mCT (EPIC-
mCT) and histology to measure cartilage quality26. The details of
these procedures were described earlier14. The animal ethic com-
mittee of the Erasmus Medical Center, Rotterdam, the Netherlands,
approved all conducted procedures. A detailed planning scheme of
all groups and conducted tests is given in Fig. 1.
Subchondral bone measurements on mCT scans
Both knees of all animals were mCT scanned under isoﬂurane
anesthesia, using a Skyscan 1176 in vivo mCT scanner (Skyscan,
Kontich, Belgium). Ten minutes of scan time was required per knee
at an isotropic voxel size of 18 mm, at a voltage of 65 kV, a current of
385 mA, ﬁeld of view of 35 mm, using a 1.0 mm aluminum ﬁlter,
over 198 with a 0.5 degree rotation step, and a 270 msec exposure
time. All datasets were segmented with a local threshold algo-
rithm27. Cortical and trabecular bone were automatically separated
using in-house software28. Using Skyscan software, both sub-
chondral plate thickness (Sb. Pl. Th. in mm) and subchondral plate
porosity (Sb. Pl. Por. inmm3) of themedial and lateral compartment
of the tibial plateau were measured24. In the tibial epiphysis, the
trabecular thickness (Tb. Th. in mm) and trabecular bone volume
fraction (BV/TV), representing the ratio of trabecular bone volume
(BV, in mm3) to endocortical tissue volume (TV, in mm3) were
measured. Ectopic bone formation (mm3) was also quantiﬁed as a
measure for osteophyte growth in these longitudinal mCT scans.
Determination of activated macrophages by SPECT/CT using 111In-
EC0800
Activated macrophages express the folate receptor-b allowing
monitoring macrophages in vivo using folate-based radio-
tracers29,30. Phosphate buffered saline (PBS, pH 6.5) DOTA-Bz-folateFig. 1. Experiment design indicating analytical time points and methods for each
experimental group. Forty 16-week-old male Wistar rats were injected with three
papain intra-articular injections (P.I.) and forced to run 15 km on a motorized tread-
mill. Animals were divided over two different groups: an untreated OA group (n ¼ 20)
and an FK506 treated group (n ¼ 20). During the experiment three longitudinal mCT
scans were made to measure subchondral bone changes24. At 6 and 12 weeks a full
analysis sequence was done in 10 animals per group (ny ¼ 10), consisting of: deter-
mination of activated macrophages using SPECT/CT in-vivo25; and cartilage analysis
with EPIC-mCT26 and histology ex-vivo.(EC0800, kindly provided by Endocyte Inc., West Lafayette, USA)31
was labeled with 111InCl3 (Covedien, Petten, The Netherlands) as
described previously14. Quality controlwas performedwith ITLC-SG
and revealed a radiochemical yield ofw91% at a speciﬁc activity of
50MBq/mg.111In-EC0800 (55MBq)was administered via the tail vein
20 h prior to scanning. SPECT/CT scans were performedwith a four-
head multiplex multi-pinhole small animal SPECT/CT camera
(NanoSPECT/CT, Bioscan Inc.,WashingtonDC, USA). All knee joints
were scanned with both helical mCT (acquisition time 5 min) and
SPECT (acquisition time 30 min). All scans were analyzed using
InVivoScope processing software (Bioscan Inc.). To reduce inter-
individual variation, the absolute difference in measured radioac-
tivity (kBq/mm3) of the OA knee joint compared to their internal
control jointwas calculated. This absolute differencewas usedwhen
comparingmeans of untreated animalswith FK506 treated animals.
Cartilage evaluation with contrast enhanced mCT and histology
Equilibrium partitioning of a contrast agent using mCT (EPIC-
mCT) has a strong correlation with cartilage sulphated-
glycosaminoglycan (sGAG) content26. Animals were euthanized
directly after the last SPECT/CT scan and both knee joints were
harvested for EPIC-mCT analysis. All specimens were incubated in
40% solution of ioxaglate (Hexabrix320, Mallinckrodt, Hazelwood,
MO, USA) for 24 h at room temperature32. EPIC-mCT was performed
on the 1176 in vivo mCT scanner (Skyscan), using the following scan
settings: isotropic voxel size of 18 mm, a voltage of 65 kV, a current of
385mA, ﬁeld of view 35mm, a 0.5 mm aluminum ﬁlter, 198 with a
0.5 degree rotation step, and a 235 msec exposure time. In all EPIC-
mCT datasets, X-ray attenuation (arbitrary gray values inversely
related to sGAG content) and cartilage thickness (mm) was calcu-
lated for cartilage of the medial and lateral plateau of the tibia14.
After EPIC-mCT, the separated parts of the knee joints were ﬁxed
in 3.7% phosphate buffered formaldehyde, decalciﬁed with formic
acid and embedded in parafﬁn. Sagittal sections were made at
300 mm intervals and stained with safranin-O with a fast green
counterstain to image the distribution of the GAGs. Sections were
stained all at once, tominimize artifacts between different samples.
Statistical analysis
Statistical analysis of vitro studies was performed as described
before11. Brieﬂy, replicate raw expression data of multiple donors
was tested for the effect of FK506 using Linear Mixed Model
regression and ‘donor’ was incorporated as a random effect to
correct for basal differences in expression between donors (SPSS
Inc., Chicago, USA).
For the in vivo study, differences between means of OA induced
and healthy knee joints within the same animal were tested using
paired t-tests at each time point for all outcome parameters
(GraphPad Software, San Diego, California, USA). When comparing
differences betweenmeans of untreated animals and FK506 treated
animals, an unpaired t-test was used at each time point for all
outcome parameters (GraphPad Software). Longitudinal data from
in vivo mCTwere additionally analyzed using generalized estimating
equations (SPSS). For all tests, P values 0.05 were considered
signiﬁcant.
Results
In vitro effects of FK506 on human osteoarthritic chondrocytes
Inhibition of Cn activity by FK506 inmonolayer cultured passage
1 osteoarthritic chondrocytes increased expressions of cartilage
speciﬁc collagens. Both low and high concentrations of FK506
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P ¼ 0.067; 620 nM by three-fold, P ¼ 0.001) and COL9 expression
(62 nM FK506 by1.8-fold, P ¼ 0.037), while no effects were found
on the ACAN/VCAN ratio or COL11 expression [Fig. 2(A)]. In cartilage
explants, the osteoarthritic chondrocytes are embedded in a ma-
trix, which might limit chondrocyte exposure to FK506. Despite the
large standard deviations in the explants cultures, we found clear
matrix-protective trends after FK506 treatment. A low dose of
FK506 was enough to induce a similar trend of increased anabolic
marker expression in explants as seen in monolayer cultured
chondrocytes [Fig. 2(B)]. Moreover, the FK506 induced changes in
chondrogenic marker expression seem to be even higher in the
explants. In line with our previous work on monolayer chon-
drocytes11, FK506 also reduced the expression of the catabolic
MMPs and important aggrecanases in the explant cultures
[Fig. 2(B)].
The FK506 induced increase in collagen expression was
conﬁrmed by immunohistology on 3D pellets cultures of osteoar-
thritic chondrocytes. FK506 clearly increased COL2 protein
expression (to 121.4% of control, P ¼ 0.009) in chondrocyte pellet
cultures, while no clear effect was seen on GAG staining [Fig. 2(C)].
In vivo effects of FK506 treatment
Bodyweight of all untreated rats at baseline was 416.4 g (411.3e
421.5 g), during 6 weeks of treadmill running this decreased non-
signiﬁcantly to a mean weight of 408.3 g (398.2e418.3 g). During
subsequent 6 weeks of rest, all rats increased in their mean body-
weight to 485.5 g (473.0e498.0 g). FK506 treated animals (mean
weight at baseline was 413.6 g; 409.4e417.8 g) also did not increase
in bodyweight during induction of OA-like articular destruction
(mean weight after 6 weeks was 418.5 g; 412.9e424.1 g). After 12
weeks their mean bodyweight was 507.1 g (498.8e515.4 g), which
was signiﬁcantly higher compared to untreated controls (P¼ 0.004)Fig. 2. RNA abundance of anabolic and catabolic markers was determined in samples from h
(grey and black bars) as compared to control (no FK506) are shown, each bar represents the
Representative images of 21-day 3D pellet cultures (C) show collagen type II immunostaining
or without 62 nM FK506. Staining intensity in FK506 pellets is expressed as mean percent(Supplementary Fig. 1 online). During the course of the experiment,
none of the animals showed signs of FK506-induced cytotoxicity,
like weight or hair loss.
Osteoarthritic changes of articular cartilage
Intra-articular papain injections combined with moderate ex-
ercise in untreated controls induced severe sGAG depletion from
bothmedial and lateral cartilage compartments of the tibia plateau.
This sGAG depleted state persisted throughout the experiment
[Fig. 3(A),(B)]. After the running protocol at 6 weeks, cartilage of the
medial compartment was slightly reduced in thickness [Fig. 3(C)].
Lateral cartilage thickness was severely degraded [Fig. 3(D)] and
resulted in almost completely denuded subchondral bone
[Fig. 3(E)]. During subsequent 6 weeks of rest medial cartilage
continued to degrade, in the lateral compartment an ongoing
decline in cartilage thickness was absent [Fig. 3(C)]. Representative
medial and lateral cartilage images from safranin-O stained his-
tology from untreated controls at 6 and 12 weeks are shown in
Fig. 4.
Compared to untreated controls, FK506 treated animals had
similar sGAG depleted cartilage in medial and lateral compart-
ments of the tibia plateau [Fig. 3(A),(B)]. Lateral cartilage was
reduced in thickness to similar extent as untreated controls
[Fig. 3(D)]. However, medial cartilage showed a trend towards
thicker ECM compared to untreated control at 6 weeks, although
this was not signiﬁcant (P ¼ 0.15). In contrast to the progressive
degradation of medial cartilage as seen in untreated controls at 12
weeks, medial cartilage thickness of FK506 treated animals
remained constant and was signiﬁcantly thicker at 12 weeks
compared to untreated controls (P ¼ 0.02) [Fig. 3(C)].
Although lateral cartilage did not differ signiﬁcantly in sGAG
content or thickness between untreated and FK506 treated rats, we
did observe a small difference between both groups. In four FK506uman osteoarthritic monolayer (A) and explant (B) cultures. Relative changes by FK506
fold-change compared to the control condition. Error bars indicate standard deviations.
(on top, in red) and sGAG staining (thionin; on bottom, in blue) of pellets cultured with
age (standard deviation) of that in control pellets *: P < 0.05, **: P < 0.01.
Fig. 3. Cartilage quality and quantity was determined from untreated OA (circles) and FK506 treated (squares) rats with equilibrium partitioning of an ionic contrast agent using
(EPIC-)mCT (AeD). The amount of sGAG (arbitrary gray values; A,B) and cartilage thickness (mm; C,D) were measured of medial (A,C) and lateral (B,D) cartilage compartments of the
tibia plateau harvested from healthy joints (blank boxes) and OA induced joints (gray boxes). Attenuation values from EPIC-mCT scans are inversely related to the sGAG content,
meaning that a high attenuation corresponds to low sGAG content. Coronal images from EPIC-mCT scans of the tibia plateau show the amount of cartilage (erosions indicated with
; and dashed lines) and sGAG content (displayed in color). *: P < 0.05, **: P < 0.01, ***: P < 0.001, error bars indicate 95% conﬁdence intervals.
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focal regions of lateral tibia cartilage that showed intact but totally
sGAG depleted ECM [Fig. 3(E)]. A difference that was also found on
safranin-O stained histology sections as shown in Fig. 4.Subchondral bone changes
Subchondral bone plate thickness of medial tibia compartment
in untreated controls and FK506 treated rats was slightly reduced
after 6 and 12 weeks of follow-up [Fig. 5(A)], but did not differ
between both groups (P ¼ 0.83). Medial plate porosity did not in-
crease in both experimental groups throughout the experiment
[Fig. 5(B)]. Lateral compartment subchondral bone thickness of
untreated OA joints was clearly increased compared to their
healthy control joint at 6 weeks (P < 0.0001), and there was also
more subchondral plate porosity (P ¼ 0.02) [Fig. 5(C),(G),(H)].
Subchondral plate thickness further increased during subsequent 6
weeks of rest (P < 0.0001). Plate porosity also seemed to increase
further, but there was no signiﬁcant difference compared to inter-
nal healthy control joints. FK506 treated animals also had a thicker
subchondral bone plate at 6 (P< 0.0001) and 12 (P< 0.0001) weeks
compared to their internal healthy control joints. When longitu-
dinal subchondral bone changes in OA joints of both groups were
analyzed with generalized estimating equations, FK506 treated rats
had thinner lateral subchondral bone plates compared to untreated
controls (P ¼ 0.03) [Fig. 5(C),(G)]. FK506 rats did not develop sub-
chondral plate porosity. This was signiﬁcantly lower at 6 weeks
(P ¼ 0.02), but not at 12 weeks anymore [Fig. 5(D),(H)]. After 6
weeks of treadmill exercise-mediated trabecular bone thickness
(P¼ 0.05) and BV/TV (P¼ 0.03) was lower in FK506 treated animals
compared to untreated controls [Fig. 5(E),(F)]. Reduced trabecular
thickness normalized during subsequent 6 weeks of rest, while the
BV/TV ratio increased compared to untreated controls (P ¼ 0.02).During 6 weeks of moderate running, FK506 treated animals
formed less ectopic bone formation compared to untreated animals
(P ¼ 0.007) [Fig. 6(B),(C)]. This difference in ectopic bone formation
between FK506 treated animals and untreated controls was still
measured after the subsequent 6 weeks of rest (P ¼ 0.04)
[Fig. 6(B),(C)].
Macrophage activation and osteophytes
Each animal received 54  2 MBq of 111In-EC0800 under iso-
ﬂurane anesthesia. There were no signiﬁcant differences of injected
activity between experimental groups. After completion of the
running protocol, both untreated and FK506 treated rats revealed
similarly increased radioactive uptake in their papain injected knee
joints compared to their internal healthy control joints
[Fig. 6(A),(C)]. After 6 subsequent weeks of rest, radioactive uptake
in OA induced joints of FK506 treated animals dropped to control
levels. The absolute difference in radioactive uptake between OA
induced and healthy control joints in FK506 treated animals was
lower compared to the absolute differences measured in untreated
controls [Fig. 6(A),(C)].
Discussion
OA is characterized by a loss of cartilage matrix, because chon-
drocytes cannot maintain tissue homeostasis due to a disturbed
balance between anabolic and catabolic activities. Inhibiting Cn
activity with immunosuppressive agents like cyclosporin A13 or
FK50611,12 increases the anabolic, while suppressing the catabolic,
activity of osteoarthritic chondrocytes. In this study, we found that
both high and low concentrations of FK506 improved the COL2/
COL1 ratio and COL9 expression in monolayer cultured human
osteoarthritic chondrocytes [Fig. 2(A)]. Then, in 3D chondrocyte
Fig. 4. Safranin-O stained histology sections of medial and lateral tibial plateau cartilage after 6 weeks and 12 weeks of follow-up. Medial cartilage of untreated OA knee joints with
depleted sGAG at 6 weeks and 12 weeks, and only mildly degraded ECM. Lateral cartilage ECM was almost totally eroded, only the calciﬁed cartilage layer remained present and
showed ECM denudation of cartilage ECM. Much less ECM degradation occurred in FK506 treated animals. The lateral compartment cartilage was severely eroded, however 4/10
rats showed focal regions with complete sGAG depleted but partially intact ECM.
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effect was seen on sGAG staining [Fig. 2(C)]. These data indicate
that Cn inhibition through FK506 may protect the structural
integrity of the ECM. Next, we studied the effects of low dose FK506
treatment in cartilage explants, in which the chondrocytes are still
embedded in their native ECM. The explants were harvested from
macroscopically ‘healthy’ cartilage areas of the degenerated side.
However, onmicroscopic level theremight be still big differences in
grade of degeneration between explants of the same donor. To limit
the effects of these differences, explants were ﬁrst pooled before
assigning them to a certain culture condition. Despite the large
standard deviations, we found a clear trend towards stimulated
anabolic but reduced catabolic activities after FK506 treatment
[Fig. 2(B)].
Finally, we evaluated whether FK506 also exerts similar favor-
able effects in a severe OA in vivomodel with a different response in
medial and lateral compartments of tibia plateau cartilage14. Six
weeks of OA-like damage induction severely erodes lateral
compartment cartilage and results in complete denudation of
subchondral bone. Medial cartilage becomes sGAG-depleted with a
slightly degraded ECM, a process that continued progressively
during the course of the experiment [Figs. 3 and 4]. FK506 treat-
ment in vivo did not increase sGAG levels nor did it protect against
sGAG loss [Fig. 3(A),(B)]. However, it did protect against structural
matrix degradation [Fig. 3(C)], which was in line with our in vitro
results [Fig. 2]. Loss of lateral cartilage matrix could not be pre-
vented with FK506 treatment [Fig. 3(D)]. Longitudinal mCT analysis
showed reduced sclerotic bone formation in the lateralcompartment of FK506 treated animals [Fig. 5(C)]. Previous ex-
periments with this severe OA model suggest that subchondral
sclerosis might develop when cartilage is completely lost and
subchondral bone is denuded14. In some FK506 treated animals we
found focal regions of cartilage on the lateral tibia plateau that
showed totally sGAG depleted but partially intact ECM. This sug-
gests, that FK506 might have delayed lateral cartilage matrix
degradation and thus reduced formation of subchondral sclerosis.
However, Cn inhibition is also known to modulate bone turnover33
and therefore may have reduced sclerosis through direct modula-
tion of osteoclast and osteoblast activity. CsA and FK506 have both
been described to induce osteopenia through anti-anabolic effects
on osteoblastic cells34 and to reduce bone formation through in-
hibition of osteoblast differentiation35,36. This could be another
explanation for the reduced development of subchondral sclerosis
in the lateral compartment, but has to be further investigated.
Another cell type that is modulated by FK506 are macro-
phages37. We determined activated macrophages using 111In-
EC0800 and quantitative SPECT/CT [Fig. 6(A)]. During OA progres-
sion, macrophages become activated25 and their TGFb/BMP-2
production has previously been related to osteophyte develop-
ment38,39. In our in vivo experiment, animals developed clear
osteophytes at the margins of the patella [Fig. 6(B)]. FK506 treat-
ment reduced osteophyte development while the total amount of
activated macrophages was equal after 6 weeks of follow-up. This
may suggest that FK506 treatment limits cytokine production by
activated synovial macrophages and previous reports on Cn inhi-
bition in macrophages showed reduced cytokine production40e42.
Fig. 5. Subchondral bone changes analyzed with longitudinal in vivo mCT in untreated OA (circles) and FK506 treated (squares) animals. Subchondral plate thickness (Sb. Pl. Th.; A,
C) and porosity (Sb. Pl. Por.; B, D) were measured in the medial (A,B) and lateral (C,D) compartment of the tibial epiphysis. Changes in trabecular thickness (Tb. Th.; E) and trabecular
bone volume fraction (BV/TV; F) were measured in tibial epiphyseal bone marrow. Representative sagittal images from binary mCT scans (G) show pore development (indicated with
;) and development of subchondral sclerosis (indicated with dashed line and *). Three-dimensional top views of the tibial plateau at different time points (H) show subchondral
pore (red color) development. *: P < 0.05, **: P < 0.01, ***: P < 0.001, error bars indicate 95% conﬁdence intervals.
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activated macrophages, which can enhance NFkb activity42 and
stimulate expression of cytokines, like TNFa, IL1a, IL1b, IL12 and
iNOS40. However, prolonged exposure to Cn inhibitors has been
shown to also secondarily inactivate this TLR induced pro-
inﬂammatory cytokine expression by negative feedback loops41.
As such, continuous FK506 exposuremay eventually suppress NFkb
pathways, but activate caspases 3 and 9 to enhance macrophage
apoptosis42. Possibly, FK506 induced macrophage apoptosis may
explain why radioactive folate uptake in our experiments was
restored to levels comparable to healthy control joints [Fig. 6(A)].
Osteoclasts are large multinucleated cells of the monocytee
macrophage hematopoietic lineage and are also inﬂuenced by
FK506. During osteoclastogenesis macrophage colony-stimulating
factor (M-CSF) and receptor activator of nuclear factor-kb ligand
(RANKL) stimulate precursor cells to acquire osteoclast character-
istics43. NFATc1 is an essential terminal differentiation factor of
osteoclastogenesis and can be blocked in a dose-dependent fashion
using CsA or FK50644. CsA and FK506 treatment suppress RANKL
stimulated osteoclastogenesis45e47, and especially inhibits late
stages of the osteoclast life cycle48. By this mechanism Cn inhibition
can diminish the activity of mature osteoclasts and reduce bone
resorption49e51. FK506 mediated suppression of osteoclastmaturation and subsequently hindered subchondral bone resorp-
tion may therefore explain why less subchondral pores were
measured in FK506 animals.
Systemic FK506 treatment is known to induce toxic side ef-
fects52. Throughout the experiment our animals gained weight (see
online Supplementary Fig. 1), and FK506 animals increased more in
weight from 6 to 12 weeks of follow-up. However, this result could
not clearly be related to side-effect of FK506, which usually results
in a loss of weight. At the end of the 12 week experiment liver
function (AST, ALT, alkaline phosphatase) and kidney function
(creatinin and urea) were normal (see online Supplementary
Fig. 2(A)). Liver and kidney histology gave no indication that
FK506 induced liver or kidney ﬁbrosis (see online Supplementary
Fig. 2(B)e(C)). Despite these promising ﬁndings, systemic FK506
treatment cannot be translated towards clinical OA care directly.
FK506 induced side effects are well described in patients after long
term use and is unacceptable for a therapeutic strategy in human
OA patients. To reduce toxicity, local intra-articular treatment may
be used, but repetitive intra-articular injections also increase the
risk of iatrogenical arthritis and should be avoided. FK506-coupled
biodegradable delivery systems might be able to prolong intra-
articular FK506 exposure and sustain long term therapeutic ac-
tion53, hopefully without systemic adverse effects.
Fig. 6. Macrophage activation determined in untreated OA animals (circles) and FK506 treated animals (squares) by injection of 111In-EC0800 using SPECT/CT. A: Quantiﬁed
radioactivity in healthy joints (blank boxes) and OA joints (gray boxes) normalized to the size of the analyzed cylindrical region of interest (kBq/mm3). Absolute differences per
animal were calculated (kBq/mm3) to reduce inter-individual variation (black boxes). A high radioactivity is related to more macrophage activation. B: Ectopic bone formation
(mm3) as a measure for osteophyte development was quantiﬁed on longitudinal bone mCT scans. C: Sagittal SPECT/CT images of knee joints from representative animals. CT images
shown in black and white were used for anatomical reference, the SPECT images are shown in color. Transaxial images from patellar bone extracted from binary mCT images show
ectopic bone formation (red color). *: P < 0.05, **: P < 0.01, ***: P < 0.001, error bars indicate 95% conﬁdence intervals.
M. Siebelt et al. / Osteoarthritis and Cartilage 22 (2014) 591e600598Conclusion
Inhibition of Cn activity with FK506 stimulated anabolic ac-
tivity, while reducing catabolic productivity of osteoarthritic
human chondrocytes. Systemic treatment with FK506 in a rat
model for severe OA also protected against cartilage ECM
degradation. Additionally, there was also less development of
subchondral sclerosis, macrophage activation and osteophyte
formation. Altogether, our data suggests that Cn inhibition with
FK506 proves to be a promising candidate for therapeutic man-
agement of OA.Contributions
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